Acuity Reports Positive Phase II Data for AMD Drug; Eyes Phase III in Mid-'07, NDA in Mid-'09

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/RNAi - Protein Synthesis

Acuity Reports Positive Phase II Data for AMD Drug; Eyes Phase III in Mid-'07, NDA in Mid-'09
By Doug Macron
September 14, 2006
RNAi News
The company said that bevasiranib was safe and well-tolerated in the uncontrolled trial, demonstrating dose-dependent decreases of the lesions that characterize wet AMD.
Paid subscription is required to view article.